{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:39:41Z","timestamp":1792697981389,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.xops.2025.100744","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T20:15:54Z","timestamp":1740168954000},"page":"100744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Real-World Evidence for Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Scoping Review"],"prefix":"10.1016","volume":"5","author":[{"given":"Varun","family":"Chaudhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Guymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Artignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2025.100744_bib1","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.2147\/OPTH.S185052","article-title":"The burden of neovascular age-related macular degeneration: a patient's perspective","volume":"12","author":"Spooner","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.oret.2024.01.004","article-title":"European unmet needs in the management of neovascular age-related macular degeneration in daily practice: data from the Fight retinal blindness! Registry","volume":"8","author":"Boudousq","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2025.100744_bib3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","article-title":"Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial","volume":"134","author":"Ross","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib4","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/s41433-020-0895-z","article-title":"Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade","volume":"34","author":"Adamis","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.xops.2025.100744_bib5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ophtha.2014.11.018","article-title":"Long-term outcomes in eyes receiving fixed-interval dosing of anti\u2013vascular endothelial growth factor agents for wet age-related macular degeneration","volume":"122","author":"Peden","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100744_bib6","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ophtha.2018.01.012","article-title":"Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti\u2013VEGF injections using a treat-extend-stop protocol","volume":"125","author":"Adrean","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100744_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","article-title":"SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States","volume":"4","author":"Khanani","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2025.100744_bib8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","article-title":"Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration","volume":"21","author":"Khachigian","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.xops.2025.100744_bib9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","article-title":"Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment","volume":"134","author":"Bressler","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3390\/cells10051049","article-title":"Anti-VEGF-resistant retinal diseases: a review of the latest treatment options","volume":"10","author":"Wallsh","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.xops.2025.100744_bib11","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific Cross MA b optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.xops.2025.100744_bib12","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1038\/s41598-024-52942-3","article-title":"Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis","volume":"14","author":"Yen","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2025.100744_bib13","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1007\/s12325-023-02675-y","article-title":"Comparative efficacy, durability and safety of faricimab in the treatment of diabetic macular edema: a systematic literature review and network meta-analysis","volume":"40","author":"Watkins","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.xops.2025.100744_bib14","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100744_bib15","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100744_bib16","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100744_bib17","first-page":"3124","article-title":"Efficacy, safety, and durability of faricimab in macular edema due to retinal vein occlusion: 72-week results from the BALATON and COMINO trials","volume":"65","author":"Ghanchi","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100744_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"key":"10.1016\/j.xops.2025.100744_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12348-022-00321-2","article-title":"Ocular adverse events associated with immune checkpoint inhibitors, a scoping review","volume":"13","author":"Martens","year":"2023","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.xops.2025.100744_bib20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ajo.2021.12.005","article-title":"Shared decision making in ophthalmology: a scoping review","volume":"237","author":"Bouaziz","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.xops.2025.100744_bib21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.survophthal.2022.08.007","article-title":"Health literacy and ophthalmology: a scoping review","volume":"68","author":"Iskander","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/1357633X17742182","article-title":"Models of care in tele-ophthalmology: a scoping review","volume":"25","author":"Caffery","year":"2019","journal-title":"J Telemed Telecare"},{"key":"10.1016\/j.xops.2025.100744_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/XEB.0000000000000050","article-title":"Guidance for conducting systematic scoping reviews","volume":"13","author":"Peters","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"10.1016\/j.xops.2025.100744_bib24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.xops.2025.100744_bib28","first-page":"2218","article-title":"FARETINA-AMD-Early treatment patterns and outcomes in patients with neovascular age-related macular degeneration initiating faricimab: an IRIS RegistryTM analysis","volume":"64","author":"Borkar","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100744_bib29","first-page":"1","article-title":"Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study","volume":"262","author":"Grimaldi","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib30","first-page":"2711","article-title":"Early structural changes with the use of Faricimab (Vabysmo) in routine clinical practice: an NHS real life experience","volume":"64","author":"Ibrahim","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100744_bib31","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s40123-023-00779-w","article-title":"Visual and anatomical outcomes after initial intravitreal faricimab injection for neovascular age-related macular degeneration in patients with prior treatment history","volume":"12","author":"Inoda","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.xops.2025.100744_bib32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/ceo.14335","article-title":"Retreatment interval lengthening achieved in two thirds of eyes with prolonged intensive anti-VEGF therapy for neovascular age-related macular degeneration after switching to faricimab","volume":"52","author":"Kenworthy","year":"2023","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib33","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study\u20136 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.xops.2025.100744_bib34","first-page":"2182","article-title":"Early outcomes of vabysmo in patients with refractory wet AMD","volume":"64","author":"Kovalova","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100744_bib35","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/medicina59040665","article-title":"Short-term outcomes of intravitreal faricimab injection for diabetic macular edema","volume":"59","author":"Kusuhara","year":"2023","journal-title":"Medicina"},{"key":"10.1016\/j.xops.2025.100744_bib36","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2147\/OPTH.S409822","article-title":"Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration","volume":"17","author":"Leung","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00417-023-06241-8","article-title":"Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration","volume":"262","author":"Maruyama-Inoue","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib38","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.3390\/jcm12237401","article-title":"Subclinical ocular changes after intravitreal injections of different anti-VEGF agents for neovascular age-related macular degeneration","volume":"12","author":"Matsubara","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.xops.2025.100744_bib39","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1007\/s00417-023-06116-y","article-title":"Short-term outcomes of intravitreal faricimab for treatment-naive neovascular age-related macular degeneration","volume":"261","author":"Matsumoto","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.oret.2023.12.001","article-title":"Rates of ocular adverse events after intravitreal faricimab injections","volume":"8","author":"Momenaei","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2025.100744_bib41","doi-asserted-by":"crossref","first-page":"8747","DOI":"10.1038\/s41598-023-35759-4","article-title":"Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan","volume":"13","author":"Mukai","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2025.100744_bib42","first-page":"280","article-title":"Early swept-source OCT-A findings after switching to faricimab in recalcitrant exAMD","volume":"64","author":"Nadel","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100744_bib43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","article-title":"Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration","volume":"262","author":"Kataoka","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib44","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/medicina59061125","article-title":"Faricimab for diabetic macular edema in patients refractory to ranibizumab or aflibercept","volume":"59","author":"Ohara","year":"2023","journal-title":"Medicina"},{"key":"10.1016\/j.xops.2025.100744_bib45","first-page":"2235","article-title":"Effects of intravitreal faricimab 6.0 mg injection on functional and anatomic outcomes in patients with neovascular age-related macular degeneration","volume":"64","author":"Pandit","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100744_bib46","first-page":"2217","article-title":"Outcomes on visual acuity, central retinal thickness and macular volume following two consecutive doses of faricimab for wAMD and DMO in non-treatment na\u00efve patients","volume":"64","author":"Patel","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100744_bib47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","article-title":"Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab","volume":"8","author":"Raimondi","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2025.100744_bib48","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.2147\/OPTH.S381503","article-title":"Faricimab for treatment-resistant diabetic macular edema","volume":"16","author":"Rush","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib49","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.2147\/OPTH.S395279","article-title":"Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration","volume":"16","author":"Rush","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib50","first-page":"2206","article-title":"Anatomical and visual outcomes of patients with active neovascular age related macular degeneration (nAMD) requiring monthly anti-VEGF treatment following switch to faricimab","volume":"64","author":"Sim","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100744_bib51","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","article-title":"Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic","volume":"37","author":"Stanga","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.xops.2025.100744_bib52","first-page":"2193","article-title":"Quantifying fluid and function in patients switched from an anti-VEGF to faricimab","volume":"64","author":"Sutter","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100744_bib53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","article-title":"Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy","volume":"8","author":"Szigiato","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2025.100744_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1167\/iovs.64.13.31","article-title":"Turnover of microaneurysms after intravitreal injections of faricimab for diabetic macular edema","volume":"64","author":"Takamura","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100744_bib55","first-page":"2251","article-title":"Short-term outcomes of switching from intravitreal brolucizumab to faricimab for neovascular age-related macular degeneration: a single-center retrospective study","volume":"64","author":"Takayama","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100744_bib56","series-title":"Early uptake and treatment patterns of faricimab among diabetic macular edema (DME) patients in the UK","first-page":"7","author":"Talks","year":"2023"},{"key":"10.1016\/j.xops.2025.100744_bib57","first-page":"2212","article-title":"Use of faricimab (VABYSMO) for highly treatment resistant CNV in wet-age related macular degeneration","volume":"64","author":"Warter","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.100744_bib58","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/bjo-2023-324394","article-title":"Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema","volume":"108","author":"Durrani","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib59","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/jcm13020385","article-title":"Comparison of loading dose between aflibercept and faricimab for neovascular age-related macular degeneration","volume":"13","author":"Hara","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.xops.2025.100744_bib60","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s10384-023-01024-4","article-title":"Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration","volume":"67","author":"Hikichi","year":"2023","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib61","author":"Zweifel"},{"key":"10.1016\/j.xops.2025.100744_bib62","author":"Bailey"},{"key":"10.1016\/j.xops.2025.100744_bib63","author":"El Khashab"},{"key":"10.1016\/j.xops.2025.100744_bib64","author":"Fazliani"},{"key":"10.1016\/j.xops.2025.100744_bib65","author":"Gillies"},{"key":"10.1016\/j.xops.2025.100744_bib66","author":"Goodchild"},{"key":"10.1016\/j.xops.2025.100744_bib67","author":"Grimaldi"},{"key":"10.1016\/j.xops.2025.100744_bib68","author":"Hassan"},{"key":"10.1016\/j.xops.2025.100744_bib69","author":"Huelin"},{"key":"10.1016\/j.xops.2025.100744_bib70","author":"Kessler"},{"key":"10.1016\/j.xops.2025.100744_bib71","author":"Lukic"},{"key":"10.1016\/j.xops.2025.100744_bib72","author":"McKibbin"},{"key":"10.1016\/j.xops.2025.100744_bib73","author":"Ibrahim"},{"key":"10.1016\/j.xops.2025.100744_bib74","author":"Narayan"},{"key":"10.1016\/j.xops.2025.100744_bib75","author":"Hwang"},{"key":"10.1016\/j.xops.2025.100744_bib76","author":"Niven"},{"key":"10.1016\/j.xops.2025.100744_bib77","author":"Pichi"},{"key":"10.1016\/j.xops.2025.100744_bib78","author":"Rehak"},{"key":"10.1016\/j.xops.2025.100744_bib79","author":"Samantaray"},{"key":"10.1016\/j.xops.2025.100744_bib80","author":"Scrivens"},{"key":"10.1016\/j.xops.2025.100744_bib81","author":"Sim"},{"key":"10.1016\/j.xops.2025.100744_bib82","author":"Suresh"},{"key":"10.1016\/j.xops.2025.100744_bib83","author":"Takada"},{"key":"10.1016\/j.xops.2025.100744_bib84","author":"Shunmugam"},{"key":"10.1016\/j.xops.2025.100744_bib85","author":"Ward"},{"key":"10.1016\/j.xops.2025.100744_bib86","author":"Zhou"},{"key":"10.1016\/j.xops.2025.100744_bib87","author":"Singer"},{"key":"10.1016\/j.xops.2025.100744_bib88","author":"Patel"},{"key":"10.1016\/j.xops.2025.100744_bib89","author":"Bailey"},{"key":"10.1016\/j.xops.2025.100744_bib90","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2025.100744_bib91","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2025.100744_bib92","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/aos.14697","article-title":"Insights into multiple sclerosis-associated uveitis: a scoping review","volume":"99","author":"Casselman","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2025.100744_bib93","doi-asserted-by":"crossref","first-page":"6","DOI":"10.17925\/USOR.2024.18.1.2","article-title":"The use of faricimab for neovascular age-related macular degeneration and diabetic macular oedema in real clinical practice","volume":"18","author":"Brant","year":"2024","journal-title":"touchREVIEWS in Ophthalmology"},{"key":"10.1016\/j.xops.2025.100744_bib94","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40942-024-00525-9","article-title":"Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME","volume":"10","author":"Penha","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.xops.2025.100744_bib95","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14712598.2024.2336087","article-title":"Global experience of faricimab in clinical settings-a review","volume":"24","author":"Sharma","year":"2024","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.xops.2025.100744_bib96","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40942-024-00566-0","article-title":"Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review","volume":"10","author":"Nasimi","year":"2024","journal-title":"Int J Retina Vitreous"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525000429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525000429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T19:44:42Z","timestamp":1772048682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914525000429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2666914525000429"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2025.100744","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Evidence for Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Scoping Review","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2025.100744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100744"}}